Application of 1-O-gallic acid acyl-β-D-glucoside extracted from Phyllanthus emblica in plant disease control

By extracting 1-O-gallic acid acyl-β-D-glucoside from the yuganzi pomace, the side effects of chemical agents and resource waste in preventing and treating potato scabs were solved, and the development of low-toxic and environmentally friendly plant-source fungicides was achieved. Promote the sustainable use of resources.

CN114568437BActive Publication Date: 2024-11-29JIMEI UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202210290149.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-03-23
Publication Date
2024-11-29
Estimated Expiration
2042-03-23

AI Technical Summary

Technical Problem

The prior art relies on chemical agents in the prevention and treatment of potato scabs, which have side effects and environmental pollution problems, and the remaining sweet potato pomace resources have not been effectively utilized.

Method used

1-O-gallic acid acyl-β-D-glucoside was extracted and isolated from the lycopene pombes, and it was found that it had the activity of inhibiting Streptomyces potato scab and was used to prepare plant-derived fungicides.

Benefits of technology

Effectively preventing and treating potato scabs, it provides a low-toxic and environmentally friendly pesticide alternative, and promotes the resource utilization of Yuganzi Potato.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003561495940000051
    Figure BDA0003561495940000051
  • Figure HDA0003561495950000011
    Figure HDA0003561495950000011
  • Figure HDA0003561495950000012
    Figure HDA0003561495950000012
Patent Text Reader

Abstract

The invention discloses an application of 1-O-gallic acid acyl-β-D-glucoside extracted from emblica emblica in plant disease prevention and treatment, wherein the plant disease is potato scab. 1-O-gallic acid acyl-β-D-glucoside is extracted from emblica emblica pomace, separated and purified, and is found for the first time to have an inhibitory effect on the activity of Streptomyces potato scab, and can be used for preventing and treating potato scab.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of active drugs, and in particular to application of 1-O-gallic acid acyl-β-D-glucoside extracted from emblica emblica in plant disease prevention and treatment. Background Art

[0002] Phyllanthus emblica L. is the fruit of the genus Phyllanthus in the Euphorbiaceae family. It is mainly distributed in tropical and subtropical areas; it is native to India and distributed in Pakistan, Malaysia, China and other countries; the largest production in China is in Fujian and Yunnan provinces. As early as 1998, it was listed as "both food and medicine" by the Ministry of Health, included in many editions of the "Pharmacopoeia of the People's Republic of China", and designated by the World Health Organization as one of the three health plants promoted for cultivation worldwide. The special composition and pharmacological activity of emblica emblica make it have great development and application value, and related industries have also developed rapidly in recent years.

[0003] At present, the development of Phyllanthus emblica mainly focuses on extraction and fresh fruit juice, and then processed into beverages, refined powders and lozenges. Its production process will produce waste such as fruit cores, pomace or medicinal residues, and a large amount of sediment, filtered solids and other types of by-products will also be produced in the preparation process of extracts. Data show that the weight of Phyllanthus emblica pomace alone can account for about 65% of the original fruit weight. Pharmaceutical companies produce nearly 100 tons of Phyllanthus emblica solid residues every year. If they are only discarded or buried, not only will the processing cost be high and the environmental pressure be great, but also a large amount of resources will be wasted. Therefore, the research on the development of Phyllanthus emblica pomace is not only conducive to preventing environmental pollution, but also can produce high value-added products, which will help to fundamentally solve the problem of pomace utilization and form a sustainable development path for the resource utilization of Phyllanthus emblica pomace.

[0004] Potato is the fourth most important food crop in the world after wheat, rice and corn. Potato can be used as a food crop for people's daily needs, and can also be used as an economic crop in a variety of industries. It has high nutritional value, strong adaptability to the environment, and great potential for increasing yields per unit area. Its development prospects are very broad. More than 20 species of potato scab pathogens have been reported, the most common of which are Streptomyces scabies, S. acidiscabies, and S. turgidiscabies. Among them, S. scabies is the main pathogen of potato scab. The symptoms of the disease include scab-like, raised or sunken lesions on the surface of the tuber, which seriously affect the quality of potatoes, reduce their market value, and cause huge economic losses to growers. Streptomyces scabies can also infect taproot crops such as radishes, beets, carrots and parsnips. Soil-borne bacterial plant diseases caused by pathogenic Streptomyces are still an important factor restricting the positive development of the potato industry in China and even the world. At present, the use of chemical agents to control the disease is effective, but it also has some side effects, such as reducing potato tubers, reducing yields, and posing a threat to the environment and human health. Therefore, finding high-efficiency and low-toxic botanical pesticides from natural plant sources is a better alternative method, which has the advantages of short cycle, low toxicity, no pollution and easy production, and is an effective way to prevent and control agricultural products in a green way. Summary of the invention

[0005] In order to solve the above problems, the present invention proposes an application of 1-O-gallic acid acyl-β-D-glucoside extracted from emblica fruit in plant disease prevention and control. The 1-O-gallic acid acyl-β-D-glucoside is extracted from emblica fruit pomace, separated and purified, and is found for the first time to have an inhibitory effect on the activity of potato scab Streptomyces, and can be used for preventing and controlling potato scab.

[0006] In order to achieve the above object, an embodiment of the present invention provides an application of 1-O-gallic acid acyl-β-D-glucoside extracted from emblica emblica in plant disease prevention and treatment, wherein the plant disease is potato scab.

[0007] According to the application of the embodiment of the present invention, 1-O-gallic acid acyl-β-D-glucoside is extracted, separated and purified from the pomace of Phyllanthus emblica, and is found for the first time to have the activity of inhibiting Streptomyces scab, and can be used for preventing and controlling potato scab.

[0008] Optionally, the preparation of the 1-O-gallic acid acyl-β-D-glucoside comprises:

[0009] The pomace of Phyllanthus emblica was soaked in 70% ethanol and extracted by ultrasonic acceleration, and the extraction was repeated for 3 times. The extracts were combined and the solvent was dried by rotary evaporation to obtain the crude ethanol extract EA.

[0010] The crude extract EA of the ethanol layer was dissolved in 50% methanol water, separated and purified using a medium-low pressure reverse phase C18 column, the flow rate was set at 30 mL / min, eluted with 25% methanol water solution, and the 15-31 min component was collected as component EA-1;

[0011] The component EA-1 was dissolved in methanol, separated and purified by Sephadex LH-20, the flow rate was set to 0.25 mL / min, methanol was used as the eluent, and the components at 3540 to 4080 min were collected as component EA-1-3;

[0012] The component EA-1-3 was dissolved in methanol and purified by high performance liquid chromatography, with a mobile phase of 1% methanol-water mixture and 0.075% trifluoroacetic acid added; flow rate: 10 mL / min; injection volume: 100 μL; column temperature: 25°C; detection wavelength: 210 nm and 280 nm; the components from 42 to 44 min were collected, which were component A-1-3-6, and were identified by nuclear magnetic resonance as 1-O-gallic acid acyl-β-D-glucoside. Therefore, the separation is carried out with the emblica pomace as raw material, the raw material is easy to obtain, the emblica pomace can be fully recycled and utilized to avoid waste; the preparation process is simple and easy to operate; the obtained 1-O-gallic acid acyl-β-D-glucoside is extracted, separated and purified from the emblica pomace, and is found for the first time to have the activity of inhibiting potato scab Streptomyces, and can be made into a botanical fungicide for potato scab, which provides a new source for the development of botanical pesticides and is of great significance for the research on the effective ingredients of natural products of Chinese medicinal materials that are both medicinal and edible.

[0013] On the other hand, the embodiment of the present invention also proposes the use of 1-O-gallic acid acyl-β-D-glucoside extracted from emblica fruit in the preparation of biological fertilizer, and the 1-O-gallic acid acyl-β-D-glucoside is used to inhibit the activity of potato scab Streptomyces. Thus, 1-O-gallic acid acyl-β-D-glucoside is extracted from emblica fruit pomace, separated and purified, and is firstly found to have the effect of inhibiting the activity of potato scab Streptomyces, and can be used as biological fertilizer.

[0014] Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 This is a graph showing an antibacterial experiment of a crude ethanol extract (EA) according to an embodiment of the present invention;

[0016] Figure 2 This is a graph showing the antibacterial experiment of the extract EA-1 according to an embodiment of the present invention;

[0017] Figure 3 This is a graph showing the antibacterial experiment of the extract EA-1-3 according to an embodiment of the present invention;

[0018] Figure 4 This is a graph showing the antibacterial effect of the extract EA-1-3-6 according to an embodiment of the present invention;

[0019] Figure 5 This is a positive control antibacterial experiment diagram according to an embodiment of the present invention;

[0020] Figure 6 This is a diagram of a solvent control antibacterial experiment according to an embodiment of the present invention;

[0021] Figure 7 This is a HPLC analysis chart of the compound 1-O-gallic acid acyl-β-D-glucoside according to an embodiment of the present invention;

[0022] Figure 8 According to the compound 1-O-gallic acid acyl-β-D-glucoside of the embodiment of the present invention 1 H-NMR spectrum;

[0023] Fig. 9 According to the compound 1-O-gallic acid acyl-β-D-glucoside of the embodiment of the present invention 13 C-NMR spectrum;

[0024] Fig.10 : is the minimum inhibitory concentration of different concentrations of 1-O-gallic acid acyl-β-D-glucoside according to the examples of the present invention. DETAILED DESCRIPTION

[0025] The technical solution of the present invention is described below through specific examples. It should be understood that the one or more method steps mentioned in the present invention do not exclude the existence of other method steps before and after the combination step or the insertion of other method steps between these explicitly mentioned steps; it should also be understood that these embodiments are only used to illustrate the present invention and are not used to limit the scope of the present invention. Moreover, unless otherwise specified, the numbering of each method step is only a convenient tool for identifying each method step, and is not intended to limit the order of arrangement of each method step or to limit the scope of the present invention. The change or adjustment of the relative relationship thereof shall also be regarded as the scope of the present invention without substantially changing the technical content.

[0026] In order to better understand the above technical scheme, the exemplary embodiments of the present invention are described in more detail below. Although exemplary embodiments of the present invention are shown, it should be understood that the present invention can be implemented in various forms and should not be limited by the embodiments set forth herein. On the contrary, these embodiments are provided in order to enable a more thorough understanding of the present invention and to enable the scope of the present invention to be fully communicated to those skilled in the art.

[0027] The test materials used in the present invention are all common commercial products and can be purchased in the market.

[0028] It should be noted that the Oxford cup method used in the following examples is: in a sterile operating table, the prepared Gao's No. 1 solid culture medium is placed next to the flame of an alcohol lamp, and 200 μL of the scab Streptomyces spore suspension prepared in advance is drawn with a sterile pipette, carefully and evenly blown on the surface of the culture medium, and the surface is evenly and lightly coated with a sterile coating rod until there is no obvious moisture on the surface, and the coating rod has a sense of pulling. After the coating is completed, the sterilized Oxford cup is placed on the surface of the culture medium, and the Oxford cup is gently pressed with sterile tweezers to make it fall into the surface of the culture medium (not too deep to touch the bottom). 200 μL of sample solution is added to each Oxford cup, and it is placed in a constant temperature incubator at 30 ° C. and cultivated. After 48 hours, it is observed whether there is an inhibition zone. Chloramphenicol (1 mg / mL) is used as a positive control group, and methanol is a solvent control group. Three parallel groups are set for each experiment.

[0029] The present invention is described below with reference to specific embodiments. It should be noted that these embodiments are merely illustrative and do not limit the present invention in any way.

[0030] Example 1

[0031] A method for preparing 1-O-gallic acid acyl-β-D-glucoside from emblica emblica, comprising the following steps:

[0032] Step 1, take 740g of fresh fruit of Phyllanthus emblica, remove the core and squeeze the juice to obtain 234g of pomace.Place the Phyllanthus emblica pomace in a 5000mL beaker, soak it with 2000mL 70% ethanol and extract it with ultrasonic acceleration for 1h, repeat the extraction 3 times, combine the extracts, drain the solvent with a rotary evaporator, and obtain 19.74g of ethanol layer crude extract (EA).

[0033] Step 2: Take 19.74 g of the crude ethanol extract (EA) obtained in step 1, dissolve it in 50 mL of 50% methanol water, use a medium-low pressure reverse phase C18 column (filler: YMC-GEL ODS-A-HG, s-50 μm; column length 4.5×35 cm), set the flow rate to 30 mL / min, elute with 25% methanol aqueous solution, and collect the 15-31 min component (EA-1).

[0034] Step 3: Dissolve 1.03 g of (EA-1) obtained in step 2 in 15 mL of 100% methanol, use Sephadex LH-20 (2.5×170 cm) and 100% methanol as eluent at a flow rate of 0.25 mL / min, and collect the 3540-4080 min components (EA-1-3).

[0035] Step 4. Collect 336.5 mg of (EA-1-3) obtained in step 3, dissolve it in 5 mL of 100% methanol, and purify it using a Huideyi preparative high performance liquid chromatograph; chromatographic column: YMC-AQ, 20×250 mm, s-10 μm, mobile phase: 1% methanol-water mixture, and then add 0.075% trifluoroacetic acid; flow rate: 10 mL / min; injection volume 100 μL; column temperature 25°C; detection wavelength: 210 nm and 280 nm; collect the 42-44 min components (EA-1-3-6) and concentrate to obtain about 82.0 mg of the compound.

[0036] The process uses the Oxford cup method to track the antibacterial activity of the crude extract and the components obtained in each step in turn, and select the parts with higher antibacterial activity for subsequent tests. Among them, the antibacterial experiment of the crude extract (EA) of the ethanol layer is as follows Figure 1 As shown in the figure, the antibacterial test of EA-1 is as follows Figure 2 As shown in the figure, the antibacterial test of EA-1-3 is as follows Figure 3 As shown in the figure, the antibacterial test of EA-1-3-6 is as follows Figure 4 As shown, the positive control 1mg / mL chloramphenicol) antibacterial experiment is as follows Figure 5 As shown, the solvent control (methanol) antibacterial experiment is as follows Figure 6 As shown, compound EA-1-3-6 was finally traced, separated and purified.

[0037] The compound EA-1-3-6 prepared in this example is a white powder, and HPLC analysis was performed on it. The HPLC parameters are as follows: HPLC model: Agilent Technologies; detector: 1260 Infinity II; chromatographic column: Welch-LP-C18 column, 4.6×250 mm, s-5 μm; liquid phase conditions: mobile phase: 1% methanol-water mixture, followed by 0.1% trifluoroacetic acid, and isocratic elution for 20 min; flow rate: 1 mL / min, column temperature: 35°C, injection volume: 20.0 μL; detection wavelength: 280 nm.

[0038] The results are as follows Figure 7 As shown, Figure 7 This is the high performance liquid chromatography detection chart of the compound at a detection wavelength of 280 nm, and the retention time is 10.370 min.

[0039] Mass spectrometry was performed on compound EA-1-3-6:

[0040] Instrument model: Q Exactive triple quadrupole tandem mass spectrometer, Bremen, Thermo, Germany;

[0041] Mass spectrometry conditions: ESI source, positive ion mode, emission current 34.6 μA; curtain gas (CUR) 20.0 psi; ion source voltage (IS) 2500 V; ion source temperature (TEM) 420 ° C; interface temperature 260 ° C; nebulizer gas (GS1) 40 psi; auxiliary gas (GS2) 40 psi; mass range 100-1000 m / z.

[0042] The molecular weight of the obtained compound EA-1-3-6: ESI-MS (m / z): 333.0801 [M+H] + ,355.0616[M+Na] + .

[0043] The compound EA-1-3-6 was subjected to NMR determination:

[0044] NMR instrument: Bruker AvanceⅡ-500 NMR instrument, test temperature: 296K; solvent: deuterated methanol; internal standard: tetramethylsilane (TMS); 1 H-NMR: 500 MHz; 13 C-NMR: 125 MHz.

[0045] The results are as follows Figure 8 and Fig. 9 . 1 H-NMR (500 MHz, CD 3 OD) data are as follows: δ: 5.66 (1H, d; J = 5.2 Hz, H-1), 3.40 (1H, m, H-2), 3.42 (1H, m, H-3), 3.47 (1H, m, H-4), 3.48 (1H, m, H-5), 3.85 (1H, d, J = 12.0 Hz, H-6a), 3.70 (1H, dd, J = 12.0, 4.2 Hz, H-6b), 7.13 (2H, s, H-2, 6);

[0046] 13 C-NMR (125 MHz, CD 3OD) data are as follows: δ: 96.1 (C-1), 74.3 (C-2), 79.0 (C-3), 71.2 (C-4), 78.3 (C-5), 62.5 (C-6), 120.9 (CG-1), 110.7 (CG-2,6), 146.7 (CG-3,5), 140.4 (CG-4), 167.2 (CG-7).

[0047] Based on the NMR data and mass spectrometry data of compound EA-1-3-6 and comparison with the literature, it is speculated that compound EA-1-3-6 is 1-O-galloyl-β-D-glucose; English name: 1-O-galloyl-β-D-glucose; molecular formula: C 13 H 16 O 10 ; Relative molecular weight: 332; The structure is as follows:

[0048]

[0049] Example 2

[0050] In the clean bench, take the strain (Streptomyces scab AMCC400023) preserved in the slant culture medium, carefully pick a single colony with the inoculation loop after burning and cooling next to the flame of the alcohol lamp, and use the plate streaking method to inoculate the pathogenic bacteria into Gao's solid culture medium No. 1, seal the edges with sealing film, and culture in a 30℃ constant temperature biochemical incubator for 48 hours. Among them, Gao's solid culture medium No. 1 (g / L): potassium nitrate: 1.0; potassium dihydrogen phosphate: 0.5; magnesium sulfate: 0.5; ferrous sulfate: 0.01; sodium chloride: 0.5; soluble starch: 20.0; agar: 15.0.

[0051] Use an inoculation loop to pick up a single colony of Streptomyces ulmoides, and streak it tightly on Gao's medium No. 1. Keep it at 28℃ for 3 days. Pipette 3mL of sterile water on the plate, gently scrape off the spores on the surface with a blade, rinse the spores on the surface of the medium in small amounts several times, and dilute to a concentration of 10 7 CFU / mL, collect into 50mL centrifuge tube to obtain bacterial liquid, and store at 4℃ for later use.

[0052] Take the 1-O-gallic acid acyl-β-D-glucoside obtained in Example 1 above and prepare it into a drug solution with a concentration of 10 mg / mL using 50% methanol aqueous solution. Take 0.5 mL of the drug solution and add it to a 2 mL centrifuge tube containing 0.5 mL of Gao's No. 1 liquid culture medium, which is tube No. 1. Take another 8 2mL centrifuge tubes containing 0.5mL Gao's No. 1 liquid culture medium and add 0.5mL of the liquid taken from the previous tube to each of them, and dilute them by half in sequence, and discard 0.5mL of the last tube (that is, draw 0.5mL of liquid from tube No. 1 and add it to tube No. 2, mix well; draw 0.5mL of liquid from tube No. 2 and add it to tube No. 3, and so on, for a total of 9 tubes. In order to ensure that the volume of each tube is consistent, draw 0.5mL from the last tube (tube No. 9) and discard it), use 0.5mL of methanol aqueous solution as the solvent control for tube No. 10, and 0.5mL of 1mg / mL chloramphenicol as the positive control for tube No. 11. Finally, add 0.5mL of the prepared bacterial solution to these 11 tubes. The final concentrations of the drugs in each tube were 5 mg / mL, 2.5 mg / mL, 1.25 mg / mL, 0.625 mg / mL, 0.3125 mg / mL, 0.15625 mg / mL, 0.078125 mg / mL, 0.0390625 mg / mL, 0.01953125 mg / mL, 0 mg / mL and 0 mg / mL, respectively. The tubes were placed in a shaker at 30°C and 150 rpm for 24 hours, and the growth of bacteria in each tube was observed. If the bacteria in the previous tube did not grow but grew in the next tube, the drug concentration corresponding to the previous tube was the minimum inhibitory concentration of 1-O-gallic acid acyl-β-D-glucoside against the bacteria. The results are as follows Fig.10 As shown, the minimum inhibitory concentration of 1-O-gallic acid acyl-β-D-glucoside against Streptomyces scab was measured to be 0.625 mg / mL, and the inhibition zone of 1-O-gallic acid acyl-β-D-glucoside (15 mg / mL) was measured to be 3.00 cm (the diameter of the Oxford cup is 7 mm).

[0053] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representation of the above terms should not be understood as necessarily being directed to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine different embodiments or examples described in this specification.

[0054] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.

Claims

1. The application of 1-O-gallic acid acyl-β-D-glucoside in plant disease prevention and control, characterized in that: The plant disease is potato scab; The preparation of the 1-O-gallic acid acyl-β-D-glucoside comprises: The pomace of Phyllanthus emblica was soaked in 70% ethanol and subjected to ultrasonic accelerated extraction, and the extraction was repeated for 3 times. The extracts were combined and the solvent was drained by rotary evaporator to obtain the ethanol layer crude extract EA. The crude extract EA of the ethanol layer was dissolved in 50% methanol water, separated and purified using a medium-low pressure reverse phase C18 column, with a flow rate of 30 mL / min, eluted with 25% methanol water solution, and the 15-31 min fraction was collected as fraction EA-1; Component EA-1 was dissolved in methanol and separated and purified using Sephadex LH-20 with a flow rate of 0.25 mL / min and methanol as the eluent. The 3540-4080 min components were collected as component EA-1-3. Component EA-1-3 was dissolved in methanol and purified by high performance liquid chromatography. The mobile phase was a 1% methanol-water mixture, and 0.075% trifluoroacetic acid was added. The flow rate was 10 mL / min. The injection volume was 100 μL. The column temperature was 25 °C. The detection wavelengths were 210 nm and 280 nm. The components from 42 to 44 min were collected, which were component A-1-3-6. They were identified by nuclear magnetic resonance as 1-O-gallic acid acyl-β-D-glucoside.

Citation Information

Patent Citations

  • Controlling agent of hardly controllable soilborne disease by gallic acid-related material, and method for controlling hardly controllable soilborne disease by using the same

    JP2009298736A

  • OPTIMAL BIOLOGICAL MARKER FOR THE BIOLOGICAL POTENCY OF Emblica Officinalis Gaertn. (AMLA) FRUIT-METHODS AND PRODUCTS THEREOF

    US20100062989A1